Acta Med. 2005, 48: 3-21

Complex View on Poisoning with Nerve Agents and Organophosphates

Jiří Bajgar

University of Defence, Faculty of Military Health Sciences, Department of Toxicology, Hradec Králové, Czech Republic

Received December 1, 2004
Accepted February 1, 2005


1. Abernethy MH, George PM, Herron JL, Evans RT. Plasma cholinesterase phenotyping with use of visible-region spectrophotometry. Clin Chem 1986; 32: 194–7.
2. Abdel-Rahman A, Shetty AK, Abou-Donia MB. Acute exposure to sarin increases blood brain barrier permeability and induces neuropathological changes in the rat brain: dose-response relationship. Neuroscience 2002; 113:721–41. <>
3. Abou-Donia MB, Lapadula DM. Mechanisms of organophosphorus ester-induced delayed neurotoxicity: Type I and Type II. Ann Rev Toxicol 1990; 30: 405–40. <>
4. Anderson DR, Harris LW, Chang FCT et al. Antagonism of soman-induced convulsions by midazolam, diazepam, and scopolamine. Drug Chem Toxicol 1997; 20:115–31. <>
5. Antonijevic B, Stojiljkovic MP, Bokonjic D, Maksimovic M, Nedeljkovic M. Effect of memantine on the permeability of the mice blood-brain barrier in soman poisoning. Toxicol Lett 2003; 144(Suppl.1):121. <>
6. Altrunas I, Delibas N, Demirci M, Kiline I, Tamer N. The effects of methidathion on lipid peroxidation and some liver enzymes: role of vitamins E and C. Arch Toxicol 2002; 76:470–3.
7. Aygun D, Doganay Z, Altintop L et al. Serum acetylcholinesterase and prognosis of acute organophosphate poisoning. J Toxicol Clin Toxicol 2002; 40:903–10. <>
8. Bachmann K. Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 1989; 9:331–8. <>
9. Bajgar J. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis and treatment. Adv Clin Chem 2004; 38:151–216. <>
10. Bajgar J. Biological monitoring of exposure to nerve agents. Brit J Ind Med 1992; 49:648–53.
11. Bajgar J. Cholinesterases and their possible influencing. Voj Zdrav Listy 1998; 67:1–6.
12. Bajgar J, Sevelova L, Krejcova G et al. Biochemical and behavioral effects of soman vapors in low concentrations. Inhal Toxicol 2004; 16:497–507. <>
13. Bajgar J. Present views on toxidynamics of soman poisoning. Acta Med (Hradec Kralove) 1996; 39:101–5.
14. Bajgar J. The influence of inhibitors and other factors on cholinesterases. Sbor Ved Pr LFUK (Hradec Kralove) 1991; 34:3–75.
15. Bajgar J. Differential inhibition of the brain acetylcholinesterase molecular forms following soman, sarin and VX intoxication in laboratory rats. Acta Medica (Hradec Kralove) 1997; 40:89–94.
16. Bajgar J. Fusek J. Kassa J. Vachek J. Relationship between toxicity and in vivo anticholinesterase potency in nerve agent poisoning. Voj Zdrav Listy 2001; 70: 18–20.
17. Bajgar J. Fusek J. Vachek J. Treatment and prophylaxis against nerve agent poisoning. ASA Newsletter 1994; 94(4):10–1.
18. Bajgar J. Prophylaxis against organophosphorus poisoning. J Med Chem Def 2003; 1:1–15.
19. Bajgar J, Hak J. Acetylcholinesterase activity and its molecular forms in rectal tissue in the diagnosis of Hirschprung’s disease. Clin Chim Acta 1979; 93:93–5. <>
20. Bajgar J, Kassa J, Fusek J. Diagnostic validity of different biochemical parameters following organophosphate poisoning. In: Proceedings from the 6th CBW Protection Symposium Stockholm, Sweden, May 10–15 1998, 1998:185–8.
21. Bajgar J, Michalek H, Bisso GM. Differential reactivation by HI-6 in vivo of Paraoxon-inhibited rat brain acetylcholinesterase molecular forms. Neurochem Int 1995; 26:347–50. <>
22. Bajgar J. Portmann R. The treatment of intoxication with selected organophosphates and carbamate: comparison of different therapeutic approaches. In: Proceedings CBMTS – Industry II, The First Congress on Chemical and Biological Terrorism. Dubrovnik 21–27 April 2001, 2001:180–4.
23. Bardin PG, van Eeden SF, Moolman JA, Foden AP, Joubert J.R. Organophosphate and carbamate poisoning. Arch Intern Med 1994; 154:1433–41. <>
24. Benschop HP, de Jong LPA. Toxicokinetics of nerve agents. In: Somani SM, Romano JA, eds. Chemical Warfare Agents: Toxicity at Low Levels, Boca Raton: CRC Press, 2001:25–81.
25. Bonham JR, Attack JR. A neural tube defect specific form of acetylcholinesterase in amniotic fluid. Clin Chim Acta 1983; 135:233–7. <>
26. Brown MA, Kelley AB. Review of health consequences from high-, intermediateand low-level exposure to organophosphorus nerve agents. J Appl Toxicol 1998; 18:393–408. <<393::AID-JAT528>3.0.CO;2-0>
27. Brown SS, Kalow W, Pilz W, Whittaker M, Woronick CL. The plasma cholinesterases: a new perspectives. Adv Clin Chem 1981; 22:1–123. <>
28. Capacio BR, Shih T-M. Anticonvulsant actions of anticholinergic drugs in soman poisoning. Epilepsia 2001; 32:604–15. <>
29. Chebabo S, Santos M, Albequerque E. Organophosphate sarin, at low concentrations, inhibits the evoked release of GABA in rat hippocampal slices. Neurotoxicology 1999; 20:871–2.
30. Cherry N, Mackness M, Durrington P. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 2002; 359:763–4. <>
31. Clark MG, Saxena A, Anderson SM et al. Behavioral toxicity of purified human serum butyrylcholinesterase in mice. In: The 4th International CB Medical Treatment Symposium, 28 April-3 May 2002, Spiez, Switzerland, 2002:Abstract No 19.
32. Cowan FM, Shih TM, Lenz DE, Madsen JM, Broomfield CA. Hypothesis for synergistic toxicity of organophosphorus poisoning-induced cholinergic crisis and anaphylactoid reactions. J Appl Toxicol 1996; 16:25–33. <<25::AID-JAT303>3.0.CO;2-5>
33. De Peyster A, Willys WO, Liebhaber M. Cholinesterase activity in pregnant women and newborns. Clin Toxicol 1994; 3296:683–96.
34. Doctor BP, Maxwell DM, Saxena A. Preparation and characterization of bioscavengers for possible use against organophosphate toxicity. In: m-CB Medical Treatment Symposium, 26–30 May 1997, Hradec Kralove, 1997:17–8.
35. Doctor BP, Saxena A, Clark MG et al. Scavenger protection against organophosphates by human serum butyrylcholinesterase. In: The 4th International CB Medical Treatment Symposium, 28 April-3 May 2002, Spiez, Switzerland, 2002: Abstract No 24.
36. Dolezal P, Vachek J, Hrabalek A. In vitro transdermal permeation of a cholinesterase reactivator HI-6. In: Brain RK, Walters KA, eds. Perspectives in percutaneous penetration, Cardiff: STS Publishing, 1988;6A:84.
37. Du Toit PW, Muller FO, van Tonder WM. Experience with the intensive care management of organophosphate insecticide poisoning. S Afr Med J 1981; 60:227–9.
38. Eddleston M, Szinicz L, Eyer P, Beuckley N. Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials. QJM Monthly J Assoc Phys 2002; 95:275–83.
39. Ellman GL, Courtney DK, Andres V, Featherstone RM. A new and rapis colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7:88–95. <>
40. Fest C, Schmidt KJ. The chemistry of organophosphorus pesticides. Second Revised Edition. Berlin, Heidelberg, New York: Springer-Verlag, 1982.
41. Fidder A, Hulst AG, Noort D et al. Retrospective detection of exposure to organophosphorus anti-cholinesterases: mass spectrometric analysis of phosphylated human butyrylcholinesterase. Chem Res Toxicol 2002; 15:582–90. <>
42. Fleisher JH, Harris LW. Dealkylation as a mechanism for ageing for cholinesterase after poisoning with pinacolyl methylphosphonofluoridate. Biochem Pharmacol 1965; 14:641–50. <>
43. Freeman SE, Dawson RM. Tacrine: a pharmacological review. Prog Neurobiol 1991; 36:257–77. <>
44. Fusek J. Tacrin and its analogues, antidotes against psychotomimetics with anticholinergic effect (in Czech). Voj Zdrav Listy 1977; 46:21–7.
45. Fusek J, Bajgar J, Vachek J. The prophylactic antidote against nerve paralytic agents – PANPAL. The Meeting of NATO TG 004 Task Group on Prophylaxis and Therapy of Chemical Agents, 11–13 September 2000, The Hague, The Netherlands, 2000.
46. Fusek J, Bajgar J, Herink J, Skopec F. New group of nerve agents: cardiovascular and respiratory effects and blood cholinesterase activity during acute intoxication with 2–dimethylaminoethyl-/dimethylamido)-fluorophosphonate in rats. Intern Rev Armed Force Med Serv 1996; 69:291–8.
47. Gersl V, Bajgar J, Hrdina R et al. Cholinesterases activities in cardiomyopathy (Daunorubicin cardiomyopathy and Dexrazoxan treated Daunorubicin cardiomyopathy in rabbits).Abstracts, XIIIth National Congress of the Turkish Pharmacological Society with International Participation. Antalya, Turkey, November 5–8, 1996:66.
48. Gersl V, Bajgar J, Hrdina R et al. Cholinesterases in Dexrazoxane-treated Daunorubicin cardiomyopathy in rabbits. Gen Physiol Biophys 1999; 18:335–46.
49. Gersl V, Bajgar J, Krs O, Hrdina R, Palicka V, Mazurová Y. Changes in cholinesterase activities after Daunorubicin administration to rabbits. Hum Exp Toxicol 1996; 15:834–8. <>
50. Gersl V, Bajgar J, Palicka V et al. Influence of drugs without anticholinesterase activity: Daunorubicin in rabbits, Proceedings of the 2nd CB Medical Treatment Symposium 7–12 July 1995, Spiez, Switzerland, 1995:214–6.
51. Gilat E, Goldman M, Lahat E et al. Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig. Arch Toxicol 2003; 77:167–72. <>
52. Gopalakrishnakone P. Microarray analysis of the human brain cell lines following exposure to a chemical agent, soman. In: Laihia K, ed. Symposium Proceedings NBC 2003, Javaskyla, 2003: 146–7.
53. Green AL. A theoretical kinetic analysis of the protective action exerted by eserine and other carbamate anticholinesterase against poisoning by organophosphorus compounds. Biochem Pharmacol 1983; 32:1717–22. <>
54. Gupta RC, Milatovic D, Dettbarn WD. Depletion of energy metabolites following acetylcholinesterase inhibitor-induced status epilepticus: protection by antioxidants. Neurotoxicology 2001; 22:271–82. <>
55. Hadacova V, Klozova E, Pitterova K, Turkova V. The screening of the enzyme and isoenzyme patterns in seeds of Alium cepa cultivar Vsetatska. Biol Plant (Prague) 1981; 23:442–8. <>
56. Herink J, Krejcova G, Bajgar J et al. Cyclosporine inhibits acetylcholinesterase activity in selected parts of the rat brain. Neurosci Lett 2003; 339:251–3. <>
57. Himuro K, Murayama S, Nishiyama K. Distal sensory axonopathy after sarin intoxication. Neurology 1998; 51:1195–7. <>
58. Johnson MK, Glinn P. Neuropathy target esterase (NTE) and organophosphorus- induced delayed polyneuropathy (OPIDP): recent advances. Toxicol Lett 1995; 82/83: 459–63. <>
59. Kadar T, Raveh L, Cohen G et al. Distribution of 3H-soman in mice. Arch. Toxicol. 1985; 58:45–9. <>
60. Kalkan S, Erdogan A, Aygoren O, Capar S, Tuncok Y. Pesticide poisonings reported to the drug and poison information center in Izmir, Turkey. Vet Hum Toxicol 2003; 45:50–2.
61. Karalliedde L, Wheeler H, Maclehose R, Murray V. Possible immediate and longterm health effects following exposure to chemical warfare agents. Public Health 2000; 114:238–48. <>
62. Kassa J. Non-specific effects of organophosphorus inhibitors of cholinesterases. Voj Zdrav Listy 1998; 67:15–9.
63. Kassa J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 2002; 6:803–16. <>
64. Kassa J, Bajgar J. The influence of pharmacological pretreatment on efficacy of HI-6 oxime in combination with benactyzine in soman poisoning in rats. Hum Exp Toxicol 1996; 15:383–8. <>
65. Kassa J, Cabal J, Bajgar J, Szinicz L. The choice: HI-6, pralidoxime or obidoxime against nerve agents? ASA Newslett 1997; 97(4):16–8.
66. Kassa J, Frankova K, Hoder P, Patocka J. A comparison of the efficacy of cholinolytics atropine and biperiden (Akineton) in combination with HI-6 on cholinergic and stressogenic effects of soman in rats. Homeostasis 1996; 37:135–6.
67. Kassa J. Fusek J. The influence of of anticholinergic drug selection on the efficacy of antidotal treatment of soman poisoned rats. Toxicology 2000; 154:67–73. <>
68. Kassa J, Fusek J, Bajgar J. The importance of PANPAL pretreatment for survival of rats poisoned with supralethal dose of soman. In: m-CB Medical Treatment Symposium, 26–30 May 1997, Hradec Kralove”, Abstracts, 1997:21–2.
69. Kassa J. Pecka M. Tichy M et al. Toxic effect of sarin in rats at three months following single or repeated low-level inhalation exposure. Pharmacol Toxicol 2001; 88:209–12. <>
70. Kassa J, Vachek J. Bajgar J, Fusek J. A combination of pyridostigmine with anticholinergic drugs: effective pharmacological pretreatment of soman-poisoned mice. ASA Newslett 2001; 84:16–9.
71. Khan S, Hemalatha R, Jeyaseelan L, Oomen A, Zachariah A. Neuroparalysis and oxime efficacy in organophosphate poisoning: a study of butyrylcholinesterase. Human Exp Toxicol 2001; 20:169–74. <>
72. Khodakovskaya OA, Vodolazskaya NA, Glukhova LD et al. Early diagnostics of delayed neurotoxicity. Toxicol Lett 2003; 144(Suppl.1):133. <>
73. Kim YB, Cheon KC, Hur GH et al. Effects of combinational prophylactics composed of physostigmine and procyclidine on soman induced lethality, seizures and brain injuries. Env Toxicol Pharmacol 2002; 11:15–21. <>
74. Kobayashi H, Li Z, Yamataka A et al. Acetylcholinesterase distribution and refractory constipation – a new criterion for diagnosis and management. Pediatr Surg Int 2002; 18:349–53. <>
75. Koplovitz I, Schulz S, Shutz M et al. Combined anticonvulsant treatment of somaninduced seizure. J Appl Toxicol 2001; 21:S53–S5. <>
76. Koponen H. Riekkinen PJ. Cerebrospinal fluid acetylcholinesterase in patients with dementia associated with schizophrenia or chronic alcoholism. Acta Psychiat Scand 1991; 83:441–3. <>
77. Krejcova G. Kassa J. Neuroprotective efficacy of pharmacological pretreatment and antidotal treatment in tabun-poisoned rats. Toxicology 2003; 185:129–39. <>
78. Kuca K, Bielavsky J, Cabal J, Bielavska M. Synthesis of a potential reactivator of acetylcholinesterase – 1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium)propane bromide. Tetrahedron Lett 2003; 44:3123–5. <>
79. Kuca K, Bielavsky J, Cabal J, Kassa J. Synthesis of a new reactivator of tabun-inhibited acetylcholinesterase. Bioorg Med Chem Lett 2003; 13:3545–7. <>
80. Kuca K, Kassa J. A comparison of the ability of a new bispyridinium oxime – 1- (hydroxyiminomethylpyridinium)-4-(carbamoylpyridinium)butane dibromide and currently used oximes to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods. J Enzyme Inhib Med Chem 2003; 18:529–35. <>
81. Kuca K, Cabal J, Kassa J. A comparison of the efficacy of a bispyridinium oxime – 1,4-bis-(2-hydroxyiminomethylpyridinium) butane dibromide and currently used oximes to reactivate sarin, tabun or cyclosarin-inhibited acetylcholinesterase by in vitro methods. Die Pharmazie 2004; 59:795–8.
82. Kuca K, Sevelová-Bartosova L, Krejcova-Kunesova G. In vitro reactivation of acetylcholinesterase inhibited by cyclosarin using bisquaternary pyridinium aldoximes K005, K033, K027 and K048. Acta Medica (Hradec Kralove) 2004; 47: 107–9.
83. Lallement G, Baille V, Baubichon D et al. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 2002; 23:1–5. <>
84. Lehre KP, Hassel B. The role of glutamate transporters in soman poisoning. The meeting of NATO TG 004 Task Group on Prophylaxis and Therapy of Chemical Agents.4–7 November 2002, Oslo, Norway, 2002.
85. Lenz DE, Broomfield AA, Cook LA. Development of immunoassay for detection of chemical warfare agents. Immunochem Technol Environ Applic ACS Symp Series 1999; 657:77–86. <>
86. Little PJ, Scimeca JA, Martin BR. Distribution of /H3/diisopropylfluorophosphate, /H3/soman, /H3/sarin, and their metabolites in mouse brain. Drug Metab Disp 1988; 16:515–20.
87. Lockridge O, Masson P. Pesticide and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurotoxicology 2000; 21: 113–26.
88. Lotti M. Organophosphorus compounds. In: Spencer PS, Schaumburg HH, eds. Experimental and Clinical Neurotoxicology”, 2nd ed., New York: Oxford University Press, 2000 pp. 898–925.
89. Lotti M,. Moretto A. Promotion of organophosphate induced delayed polyneuropathy by certain esterase inhibotors. Chem Biol Interact 1999; 119–120:519–24. <>
90. Luo CY, Leader H, Radic Z et al. Two possible orientations of the HI-6 molecule in the reactivation of organophosphate/inhibited acetylcholinesterase. Biochem Pharmacol 2003; 66:387–92. <>
91. Malik GM, Mubarik M, Romshoo GJ. Organophosphorus poisoning in the Kashmir Valley, 1994 to 1997. N Engl J Med 1998; 338:1998–178. <>
92. Masopust J. Clinical biochemistry of ciliary ducts. Part 2. Tests for bile production and excretion, proteosynthesis, and detoxification (in Czech). Biochem Clin Bohemoslov 1983; 12:363–76.
93. Marrs TC, Maynard RL, Sidell FR. Chemical warfare agents. Toxicology and treatment. Chicester, New York, Brisbane, Toronto, Singapore: J. Wiley and Sons., 1996.
94. Massoulié J, Pezzementi L, Bon S, Krejci E, Vallette FM. Molecular and cellular biology of cholinesterases. Progr Neurobiol 1993; 41:31–91. <>
95. Maxwell DM, Lenz DE, Groff WA, Kaminskis A, Froehlich HL. The effect of blood flow and detoxification on in vivo cholinesterase inhibition by soman in rats. Toxicol Appl Pharmacol 1987; 88:66–76. <>
96. McDonough JH. Animal models of nerve agent intoxication and treatment of human nerve agent casualties: Identification of key variables for immediate therapy. The meeting of NATO TG 004 Task Group on Prophylaxis and Therapy of Chemical Agents.4–7 November 2002, Oslo, Norway, 2002.
97. McDonough JH, McMonagle J, Copeland T, Zoeffel D, Shih TM. Comparative evaluation of benzodiazepines for control of soman-induced seizures. Arch Toxicol 1999; 73:473–8. <>
98. Mc Donough JH, Zoeffel LD, McMonagle J, Copeland TL, Smith CD, Shih TM. Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs. Epilepsia 2000; 38:1–14.
99. Meshulam Y, Cohen G, Chapman S, Alkalai D, Levy A. Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine. J Appl Toxicol 2001; 21(Suppl.1):S75–S8. <>
100. Moore DH, Bioscavengers as antidotes for organophosphorus (OP) agents. In: Proceedings of the 2nd CB Medical Treatment Symposium, 7–12 July 1996, Spiez, Switzerland, 1996:330–49.
101. Morita H, Yanagisawa T, Nakajima M et al. Sarin poisoning in Matsumoto, Japan. Lancet 1995; 346:290–3.
102. Musser G. Better killing through chemistry. Sci Am 2001; 285:20–1. <>
103. Nagao M, Takatori T, Matsuda Y, Nakajima M, Iwase H, Iwadare K. Definitive evidence for the acute sarin poisoning in diagnosis in the Tokyo subway. Toxicol Appl Pharmacol 1997; 144:198–203. <>
104. Nakajima T, Sato S, Morita H, Nakajima T. Sarin poisoning of a rescue team in the Matsumoto sarin incident in Japan. Occup Environ Med 1997; 54:697–701. <> <PubMed>
105. Noort D, Benschop HP, de Jong LPA. Methods for retrospective detection of exposure to toxic scheduled chemicals: an overview. Voj Zdrav Listy 2001; 70:14–7.
106. Noort D, Hulst AG, Plattenburg DHJM, Polhuijs M, Benschop HP. Quantitative analysis of O-isopropyl methylphosphonic acid in serum samples of Japanese citizens allegedly exposed to sarin: Estimation of internal dose. Arch Toxicol 1998; 72:671–5. <>
107. Noort D, Benschop HP, Black RM. Biomonitoring of exposure to chemical warfare agents: a review. Toxicol Appl Pharmacol 2002; 184:116–26. <>
108. Ohbu S, Yamashina A, Takasu N. Sarin poisoning in Tokyo subway. South Med J 1997; 90:587–93. <>
109. Ohtomi S, Takase M, Kunagoi F. A clinical experience in Japan Self Defence Force (JSDF) Central Hospital. Intern Rev Armed Force Med Serv 1996; 69:97–102.
110. Okomura T, Suzuki K, Fukuda A. The Tokyo subway sarin attack. Disaster menagement. Part 2: hospital response. Acad Emerg Med 1998; 5:618–24. <>
111. Patocka J, Kassa J. Huperzine A – prospective prophylactic antidote against organophosphate warfare agent poisoning. ASA Newslett 1999; 99(2):16–9.
112. Patočka J, Kuča K, Jun D. Acetylcholinesterase and butyrylcholinesterase – important enzymes of human body. Acta Med (Hradec Kralove) 2004; 47: 215–30. <>
113. Perry RH, Wilson ID, Bober MJ et al. Plasma and erythrocyte acetylcholinesterase in senile dementia of Alzheimer type. Lancet 1982; 1:174–5. <>
114. Polhuijs M, Langenberg JP, Benschop HP. New method for retrospective detection of exposure to organophosphorus anticholinesterases: application to alleged sarin victims of Japanese terrorists. Toxicol Appl Pharmacol 1997; 146:156–61. <>
115. Rotenberg JS, Newmark J. Nerve attacks on children: diagnosis and management. Pediatrics 2003; 112:648–58. <>
116. Sakurada K, Matsubara K, Shimizu K et al. Pralidoxime iodide (2–PAM) penetrates across the blood-brain barrier. Neurochem Res 2003; 28:1401–7. <>
117. Saxena A, Doctor BP, Sun W et al. HuBChE: a bioscavenger for protection against organophosphate chemical warfare agents. US Army Med Dept 2004;PB 8/04/10:23–9.
118. Sevelova L, Bajgar J, Saxena A, Doctor BP. Protective effect of equine butyrylcholinsterase in inhalation intoxication of rats with sarin: determination of blood and brain cholinesterase activities. Inhal Toxicol 2004; 16:531–6. <>
119. Sevelova L, Vachek J. Effect of methoxime combined with anticholinergic, anticonvulsant or anti-HCN drugs in tabun-poisoned mice. Acta Med (Hradec Kralove) 2003; 46:109–12.
120. Shapira S, Kadar T, Cohen G, Chapman S, and Raveh L. Effects of CBDP and MEPQ on the toxicity and distribution of /H3/-soman in mice. Arch Toxicol 1990; 64:663–8. <>
121. Shih TM, Penetar DM, McDonough JH, Romano JA, King JM. Age-related differences in soman toxicity and in blood and regional cholinesterase activity. Brain Res Bull 1990; 24:429–36. <>
122. Shih TM, Duniho SM, McDonough JH. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol Appl Pharmacol 2003; 188:69–80. <>
123. Silveire CL, Eldefrawi AT, Eldefrawi ME. Putative M2 muscarinic receptors of rat heart have high affinity for organophosphorus anticholinesterases. Toxicol Appl Pharmacol 1990; 103:474–81. <>
124. Slizova D, Bajgar J, Krs O, Pospisilova B. Changes of the rat liver microcirculation following sublethal intoxication with soman. Voj Zdrav Listy (Suppl) 1997; 66:39.
125. Slizova D, Krs O, Bajgar J, Pospisilova B. Changes in microvascularization of some rat organs following soman poisoning. Sb Ved Pr LFUK (Hradec Kralove) 1995; 38:115–22.
126. Solberg Y, Belkin M. The role of excitotoxicity in organophopshporous nerve agents central poisoning. TIPS 1997; 18:183–5.
127. Soreq H, Gnatt A, Loewenstein Y, Neville LF. Excavations into the active sitegorge of cholinesterase. TIBS 1992; 17:353–8.
128. Sungur M, Guven M. Intensive care management of organophosphate insecticide poisoning. Crit Care 2001; 5:211–5. <> <PubMed>
129. Sweeney R, Maxwell D. A theoretical expression for the protection associated with stoichiometric and catalytic scavengers in a single compartment model of organophosphorus poisoning. The meeting of NATO TG 004 Task Group on Prophylaxis and Therapy of Chemical Agents.4–7 November 2002, Oslo, Norway. 2002.
130. Talbot BG, Anderson DR, Harris LW, Zarbrough LW, Lennox WJ. A comparison of in vivo and in vitro rates of ageing of soman-inhibited erythrocyte acetylcholinesterase in different animal species. Drug Chem Toxicol 1988; 11:289–395. <>
131. Tonkopii V. Structure and efficiency of carbamates as drugs for prophylaxis against OP poisoning. In: Laihia K, ed. Symposium Proceedings, NBC 2003, Jyvaskyla, 2003: 140–1.
132. Tonkopii V. Oxidative stress in the mechanism of organophosphates neurotoxicity. Toxicol Lett 2003; 144(Suppl.1):132. <>
133. Tryphonas LK, Clement J. Soman toxicity: morphogenesis of CNS and heart lesions. In: Poceedings of the CB MTS, CIBIAC, ASA, Batelle, Edgewood USA, NC Lab Spiez, Switzerland, 2.25–2.26,1995.
134. Vachek J, Gersl V, Fusek J, Krs O, Skopec F, Bajgar J. Toxicities of O-alkyl S- (2–dialkylaminoethyl) methyl phosphonothiolates (V-compounds). Acta Med (Hradec Kralove) 1996; 39:67–71.
135. Van Helden HPM, Bueters TJH. Protective activity of adenosine receptor antagonists in the treatment of organophosphate poisoning. TIPS 1999; 20:438–41.
136. Van der Schans MJ, Noort D, Fidder A, Degenhardt CEAM, Benschop HP, Langenberg JP. Retrospective detection of exposure to organophosphorus anticholinesterases: fluoride reactivation and mass spectrometric analysis of phosphylated human butyrylcholinesterase. The meeting of NATO TG 004 Task Group on Prophylaxis and Therapy of Chemical Agents.4–7 November 2002, Oslo, Norway, 2002.
137. Ward TR, Ferris DJ, Tilson HA, Mundy WR. Correlation of anticholinesterase activity of a series of organophosphates with their ability to compete with agonist binding to muscarinic receptors. Toxicol Appl Pharmacol 1993; 122:300–7. <>
138. Weissmann-Brenner A, David A, Vidan A, Hourvitz A. Organophosphate poisoning: a multihospital survey. Isr Med Assoc J 2002; 4:573–6.
139. Whittaker M. Plasma cholinesterase variants and the anaesthesist. Anaesthesia 1980; 35:174–97. <>
140. Worek F, Mast U, Kiderlen D, Diepold C, Eyer P. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 1999; 288:73–90. <>
141. Worek F, Reiter G, Eyer P, Szinicz L. Reactivation kinetics o acetylcholinesterase from different species inhibited by highly toxic organophosphates. Arch Toxicol 2002; 76:523–9.
142. Yokoyama K, Araki S, Murata K et al. Chronic neurobehavioral and central autonomic nervous system effects in Tokyo subway sarin poisoning. J Physiol 1998; 92:317–23.
143. Yoshida T. Toxicological reconsideration of organophosphate poisoning in relation to the possible nerve-gas sarin-poison disaster happened in Matsumoto-city, Nagano. Jap J Toxicol Environ Hlth 1994; 40:486–97. <>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal